GSK US news http://www.us-gsk.com/html/media-news/ GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news. GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement for retigabine http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10130.htm GlaxoSmithKline and Valeant Pharmaceuticals International today announced that they have entered into an exclusive worldwide collaboration agreement for the investigational drug retigabine Thu, 28 Aug 2008 13:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10130.htm GSK to post quarterly US grants report http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10126.htm GlaxoSmithKline (NYSE: GSK) today announced that, beginning in February 2009, the company will proactively report educational and charitable grants provided to US health-related organizations. Thu, 21 Aug 2008 13:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10126.htm New study suggests increasing prescription co-payments for chronic diseases may worsen health disparities, adversely affect health http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10124.htm Patients in low-income geographic areas are more sensitive to cost-sharing increases Tue, 19 Aug 2008 14:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10124.htm GSK begins shipments of Fluarix® and FluLaval® to U.S. customers for 2008-2009 influenza season http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10123.htm GSK anticipates delivery of at least half of shipments by the end of August Mon, 11 Aug 2008 18:30:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10123.htm Head-to-head 96-week study shows EPZICOM is comparable to Truvada in efficacy and safety measures in HIV treatment-naive patients http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10118.htm GlaxoSmithKline (NYSE: GSK)today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada® (tenofovir DF + emtricitabine) as a first-line option for the treatment of HIV. Thu, 7 Aug 2008 18:30:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10118.htm Analysis of six clinical trials finds EPZICOM effective in treatment-naive HIV patients with both high and low baseline viral loads http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10120.htm GlaxoSmithKline (NYSE: GSK) announced that a retrospective analysis of six clinical trials found that anti-HIV regimens containing EPZICOM (abacavir + lamivudine) were effective in treatment-naïve patients regardless of baseline viral loads. Thu, 7 Aug 2008 18:30:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10120.htm Pooled-analysis of 54 clinical studies shows no increased risk of heart attack with Abacavir therapy http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10117.htm GlaxoSmithKline (GSK) announced today that a review of data from over 14,600 patients in 54 clinical studies showed no increased risk of myocardial infarction associated with the anti-HIV medication abacavir. Wed, 6 Aug 2008 18:30:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10117.htm GlaxoSmithKline and Genmab announce positive top-line results in ofatumumab chronic lymphocytic leukaemia pivotal study http://us.gsk.com/html/media-news/pressreleases/2008/2008_pressrelease_10091.htm Phase III pivotal study of ofatumumab in refractory CLL meets primary endpoint Thu, 31 Jul 2008 15:30:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_pressrelease_10091.htm Head-to-head study results demonstrated no significant difference between NicoDerm® CQ® and Chantix (varenicline tartrate) in long term quit rates http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10121.htm Therapeutic nicotine (TN) remains first-line treatment option Mon, 28 Jul 2008 19:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10121.htm GlaxoSmithKline and the Harvard Stem Cell Institute announce a unique collaboration to enable the discovery of new medicines http://us.gsk.com/html/media-news/pressreleases/2008/2008_pressrelease_10089.htm - Industry and academia link up in pioneering agreement Thu, 24 Jul 2008 14:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2008/2008_pressrelease_10089.htm